Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Tositumomab
Drug ID BADD_D02252
Description Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine).
Indications and Usage For treatment of non-Hodgkin's lymphoma (CD20 positive, follicular)
Marketing Status approved; investigational
ATC Code Not Available
DrugBank ID DB00081
KEGG ID D08621
MeSH ID C119496
PubChem ID Not Available
TTD Drug ID D0I2AV
NDC Product Code Not Available
UNII 0343IGH41U
Synonyms tositumomab I-131 | 131I-tositumomab | anti-B1 antibody I-131 | tositumomab conjugate with 131I | iodine (131I) tositumomab | iodine-131 tositumomab | I-131 anti-B1 antibody | iodine-131 anti-B1 monoclonal antibody | iodine-131-labeled anti-CD20 antibody | iodine-131-tositumomab | tositumomab iodine-131 | iodine-131 anti-B1 antibody | 131I anti-B1 | Bexxar
Chemical Information
Molecular Formula Not Available
CAS Registry Number 208921-02-2
SMILES Not Available
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Injection site hypersensitivity08.02.03.006; 10.01.03.017; 12.07.03.006---
Laryngospasm22.04.02.002--
Leukaemia01.10.03.001; 16.01.03.001--
Malignant melanoma16.03.01.001; 23.08.01.001---
Myalgia15.05.02.001--
Myelodysplastic syndrome01.10.04.001; 16.01.04.001--
Nausea07.01.07.001--
Neck pain15.03.04.009--
Neutropenia01.02.03.004---
Oedema peripheral02.05.04.007; 08.01.07.007; 14.05.06.011--
Pain08.01.08.004--
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
Pleural effusion22.05.02.002--
Pneumonia11.01.09.003; 22.07.01.003---
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001---
Rhinitis11.01.13.004; 22.07.03.006--
Sepsis11.01.11.003--
Serum sickness10.01.03.004; 12.02.08.004--
Skin cancer16.03.02.002; 23.08.02.002---
Skin infection11.01.12.003; 23.11.04.007--
Somnolence17.02.04.006; 19.02.05.003--
Thrombocytopenia01.08.01.002---
Vasodilatation23.06.05.006; 24.03.02.003---
Viral infection11.05.04.001---
Vomiting07.01.07.003--
Weight decreased13.15.01.005--
Haemorrhage24.07.01.002---
Lung neoplasm malignant16.19.02.001; 22.08.01.001---
The 2th Page    First    Pre   2 3    Next   Last    Total 3 Pages